NCT05255237View on ClinicalTrials.gov

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

PHASE3CompletedINTERVENTIONAL

Enrollment

315

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions

Alopecia Areata

Interventions

DRUG

Jaktinib

75mg BID

Trial Locations (1)

Unknown

11 Xizhimen South Street, Beijing

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY